Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 11040
Country/Region: Ethiopia
Year: 2018
Main Partner: United Nations High Commissioner for Refugees
Main Partner Program: NA
Organizational Type: Multi-lateral Agency
Funding Agency: enumerations.State/PRM
Total Funding: $770,072 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $39,379
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $9,845
Care: Pediatric Care and Support (PDCS) $39,379
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $113,006
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $63,992
Sexual Prevention: Other Sexual Prevention (HVOP) $164,823
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $319,958
Treatment: Pediatric Treatment (PDTX) $19,690
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
TX_CURR 25-29, Female, Positive 2019 71
TX_CURR 25-29, Male, Positive 2019 29
TX_CURR 30-34, Female, Positive 2019 207
TX_CURR 30-34, Male, Positive 2019 59
TX_CURR 35-39, Female, Positive 2019 188
TX_CURR 35-39, Male, Positive 2019 70
TX_CURR 40-49, Female, Positive 2019 438
TX_CURR 40-49, Male, Positive 2019 311
TX_CURR Age/Sex: <1-9 2019 6
TX_CURR Age/Sex: 10-14 Female 2019 23
TX_CURR Age/Sex: 10-14 Male 2019 29
TX_CURR Age/Sex: 15-19 Female 2019 76
TX_CURR Age/Sex: 15-19 Male 2019 62
TX_CURR Age/Sex: 20-24 Female 2019 94
TX_CURR Age/Sex: 20-24 Male 2019 62
TX_CURR Age/Sex: 50+ Female 2019 294
TX_CURR Age/Sex: 50+ Male 2019 175
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 2,196
TX_CURR Sum of age/sex disaggregates 2019 138
TX_NEW 25-29, Female, Positive 2019 4
TX_NEW 30-34, Female, Positive 2019 12
TX_NEW 30-34, Male, Positive 2019 4
TX_NEW 35-39, Female, Positive 2019 10
TX_NEW 35-39, Male, Positive 2019 4
TX_NEW 40-49, Female, Positive 2019 25
TX_NEW 40-49, Male, Positive 2019 24
TX_NEW By Age/Sex: 1-9 2019 2
TX_NEW By Age/Sex: 10-14 Female 2019 5
TX_NEW By Age/Sex: 10-14 Male 2019 2
TX_NEW By Age/Sex: 15-19 Female 2019 1
TX_NEW By Age/Sex: 50+ Female 2019 9
TX_NEW By Age/Sex: 50+ Male 2019 8
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 114
TX_NEW Sum of Age/Sex disaggregates 2019 25
VMMC_CIRC By Age: 10-14 2019 1,729
VMMC_CIRC By Age: 15-19 2019 556
VMMC_CIRC By Age: 2 months - 9 years 2019 1
VMMC_CIRC By Age: 20-24 2019 258
VMMC_CIRC By Age: 25-29 2019 134
VMMC_CIRC By Age: 50+ 2019 10
VMMC_CIRC By circumcision technique: Surgical VMMC 2019 534
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2019 2,688
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2019 2,687
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2019 2,553